Glenmark Life Sciences
Glenmark Life Sciences Performance
Day Range
- Low 630.35
- High 649.90
52 Week Range
- Low 370.00
- High 675.00
- Open Price640.10
- Previous Close640.30
- Volume79331
Start SIP in Glenmark Life Sciences
Start SIPGlenmark Life Sciences Investment Rating
-
Master Rating:
-
Glenmark Life Sciences has an operating revenue of Rs. 2,335.86 Cr. on a trailing 12-month basis. An annual revenue growth of 2% is not great, Pre-tax margin of 29% is great, ROE of 21% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 15% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 5% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 84 which is a GOOD score indicating consistency in earnings, a RS Rating of 60 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 131 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 595 | 578 | 621 | 541 | 509 | 490 | 514 |
Operating Expenses Qtr Cr | 428 | 385 | 415 | 395 | 366 | 343 | 372 |
Operating Profit Qtr Cr | 167 | 193 | 206 | 145 | 144 | 147 | 142 |
Depreciation Qtr Cr | 13 | 13 | 12 | 11 | 10 | 10 | 10 |
Interest Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Qtr Cr | 40 | 47 | 51 | 36 | 37 | 38 | 39 |
Net Profit Qtr Cr | 119 | 135 | 146 | 105 | 107 | 109 | 99 |
Glenmark Life Sciences Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹630.39
- 50 Day
- ₹627.49
- 100 Day
- ₹612.67
- 200 Day
- ₹575.04
- 20 Day
- ₹629.83
- 50 Day
- ₹627.75
- 100 Day
- ₹629.34
- 200 Day
- ₹554.82
Glenmark Life Sciences Resistance and Support
Resistance | |
---|---|
First Resistance | 646.88 |
Second Resistance | 658.17 |
Third Resistance | 666.43 |
RSI | 55.67 |
MFI | 56.93 |
MACD Single Line | 1.23 |
MACD | 2.37 |
Support | |
---|---|
First Resistance | 627.33 |
Second Resistance | 619.07 |
Third Resistance | 607.78 |
Glenmark Life Sciences Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 81,998 | 4,910,860 | 59.89 |
Week | 111,289 | 8,005,018 | 71.93 |
1 Month | 118,760 | 8,572,097 | 72.18 |
6 Month | 219,283 | 13,172,335 | 60.07 |
Glenmark Life Sciences Result Highlights
Glenmark Life Sciences Synopsis
NSE-Medical-Ethical Drugs
Glenmark Life Scienc belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 2161.22 Cr. and Equity Capital is Rs. 24.51 Cr. for the Year ended 31/03/2023. Glenmark Life Sciences Ltd. is a Public Limited Listed company incorporated on 23/06/2011 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L74900PN2011PLC139963 and registration number is 139963.Market Cap | 7,788 |
Sales | 2,336 |
Shares in Float | 2.08 |
No of funds | 79 |
Yield | 6.84 |
Book Value | 3.64 |
U/D Vol ratio | 1.7 |
LTDebt / Equity | |
Alpha | 0.13 |
Beta | 0.68 |
Glenmark Life Sciences
Owner Name | Sep-23 | Jun-23 | Mar-23 | Dec-22 |
---|---|---|---|---|
Promoters | 82.85% | 82.85% | 82.85% | 82.85% |
Mutual Funds | 0.38% | 0.52% | ||
Insurance Companies | 0.15% | 0.07% | ||
Foreign Portfolio Investors | 4.39% | 3.27% | 3.28% | 4.45% |
Financial Institutions/ Banks | ||||
Individual Investors | 9.21% | 10.02% | 10.87% | 9.78% |
Others | 3.02% | 3.34% | 3% | 2.85% |
Glenmark Life Sciences Management
Name | Designation |
---|---|
Mr. Glenn Saldanha | Chairman & Non-Exe.Director |
Dr. Yasir Rawjee | Managing Director & CEO |
Mr. Vinod Naik | Executive Director |
Mr. V S Mani | Non Executive Director |
Mr. Sridhar Gorthi | Independent Director |
Mrs. Manju Agarwal | Independent Director |
Mr. Taruvai Laxminarayanan Easwar | Independent Director |
Ms. Gita Nayyar | Independent Director |
Glenmark Life Sciences Forecast
Price Estimates
Glenmark Life Sciences Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-10-20 | Quarterly Results | |
2023-10-09 | Interim Dividend | |
2023-07-21 | Quarterly Results | |
2023-04-27 | Audited Results | |
2023-03-16 | Interim Dividend |
Date | Purpose | Remarks |
---|---|---|
2023-10-17 | INTERIM | Rs.22.50 per share(1125%)Interim Dividend |
2023-03-24 | INTERIM | Rs.21.00 per share(1050%)Interim Dividend |
2021-11-23 | INTERIM | Rs.10.50 per share(525%)Interim Dividend |
Glenmark Life Sciences FAQs
What is Share Price of Glenmark Life Sciences ?
Glenmark Life Sciences share price is ₹635 As on 06 December, 2023 | 03:17
What is the Market Cap of Glenmark Life Sciences ?
The Market Cap of Glenmark Life Sciences is ₹7787.8 Cr As on 06 December, 2023 | 03:17
What is the P/E ratio of Glenmark Life Sciences ?
The P/E ratio of Glenmark Life Sciences is 15.4 As on 06 December, 2023 | 03:17
What is the PB ratio of Glenmark Life Sciences ?
The PB ratio of Glenmark Life Sciences is 3.6 As on 06 December, 2023 | 03:17